Mealey's Drugs & Devices

  • February 04, 2021

    McKinsey To Pay $573M To Settle States’ Probes Into Its Opioids Consulting Roles

    NEW YORK — Management consulting company McKinsey & Co. Inc. on Feb. 4 agreed to pay $573,919,331 to 49 states, the District of Columbia and five U.S. territories to settle attorneys general investigations into the company’s role in advising opioids manufacturers, including Purdue Pharma LP, Johnson & Johnson and Endo International PLC, on how to sell more of the addictive drugs even during the opioid epidemic.

  • February 03, 2021

    Opioids MDL Judge Denies Class Certification For Guardians Of ‘Opioid Babies’

    CLEVELAND — The Ohio federal judge overseeing the opioids multidistrict litigation on Feb. 1 denied a motion to certify a class of guardians of children with neonatal abstinence syndrome (NAS) allegedly caused by their mothers’ use of opioids.

  • February 02, 2021

    Mass Tort Cases For Drugs, Medical Devices

    New developments in the following mass tort drug and device cases are marked in boldface type.

  • February 02, 2021

    Federal Circuit Vacates Attorney Fee Denial In Gardasil Injury Case

    WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on Jan. 8 ruled that a vaccine court special master erred in finding that there was no reasonable basis for a mother to file a compensation petition for a Gardasil vaccine injury and for denying the mother’s subsequent motion for statutory attorney fees.

  • February 02, 2021

    EpiPen MDL Judge Unseals Summary Judgment, Daubert Opinions After 44 Days

    KANSAS CITY, Kan. — Forty-four days after they were issued, a Kansas federal judge overseeing the EpiPen multidistrict litigation on Jan. 29 ordered his Dec. 17 summary judgment and expert witness opinions unsealed and partially redacted copies released by the court clerk (In Re:  EpiPen [Epinephrine Injection, USP] Marketing, Sales Practices and Antitrust Litigation, MDL Docket No. 2785, No. 17-md-2785, D. Kan.).

  • February 02, 2021

    Valsartan MDL Judge Denies, Grants Dismissal Of Some Claims On Pleadings

    CAMDEN, N.J. — The New Jersey federal judge overseeing the valsartan multidistrict litigation on Jan. 29 issued an opinion granting and denying defense motions to dismiss the plaintiffs’ fraudulent misrepresentation and failure-to-warn claims for alleged pleading deficiencies.

  • February 02, 2021

    Bankruptcy Judge Confirms Liquidation Plan For Opioids Maker Insys

    WILMINGTON, Del. — A Delaware federal bankruptcy judge on Jan. 16 issued findings of fact, conclusions of law and an order confirming a joint Chapter 11 bankruptcy liquidation plan for former opioids manufacturer Insys Therapeutics Inc. and its related companies.

  • February 01, 2021

    Massachusetts High Court Reverses Preemption Denial In Medical Device Case

    BOSTON — The Massachusetts Supreme Judicial Court on Jan. 29 reversed a trial court’s denial of a preemption motion by Genzyme Corp. to dismiss a Synvisc-One medical device injury case, saying the plaintiff asserted claims that paralleled federal requirements but were insufficiently pleaded.

  • January 29, 2021

    FTC Sues Endo, Impax, Amneal For Antitrust Pact To Monopolize Opana ER Opioids Market

    WASHINGTON, D.C. — The U.S. Federal Trade Commission on Jan. 25 filed a civil antitrust complaint against Endo Pharmaceuticals Inc., Impax Laboratories LLC and Amneal Pharmaceuticals Inc., alleging that the defendants’ 2017 agreement sought to eliminate competition for the opioid oxymorphone ER.

  • January 28, 2021

    AstraZeneca Named In Stock-Drop Suit Over COVID-19 Vaccine Misrepresentations

    NEW YORK — An investor sued biopharmaceutical company AstraZeneca PLC and certain of its senior executives in New York federal court on Jan. 26, alleging that the defendants misrepresented the success of clinical trials for the company’s COVID-19 vaccination candidate in violation of federal securities laws.

  • January 28, 2021

    10th Circuit: Silicone Breast Implant Case Preempted; Motion To Amend Missed Mark

    DENVER — The 10th Circuit U.S. Court of Appeals on Jan. 26 affirmed that two plaintiffs’ product liability claims for allegedly leaking silicone breast implants are preempted by federal law and that the plaintiffs failed to follow procedure to file an amended complaint.

  • January 27, 2021

    Valsartan MDL Judge Issues  3rd Ruling On Motions To Dismiss Master Complaints

    CAMDEN, N.J. — The New Jersey federal judge overseeing the valsartan multidistrict litigation on Jan. 22 issued his third opinion on defense dismissal motions, this time allowing warranty claims for some states but dismissing the same claims in other states.

  • January 26, 2021

    Plaintiff Leadership Named In Elmiron Eye Injury MDL

    TRENTON, N.J. — The New Jersey federal judge overseeing the Elmiron multidistrict litigation on Jan. 22 appointed plaintiffs’ counsel to various leadership positions.

  • January 26, 2021

    Taxotere Hair Loss MDL Bellwether Case Dismissed As Time-Barred

    NEW ORLEANS — The Louisiana federal judge overseeing the Taxotere hair loss multidistrict litigation on Jan. 22 granted judgment in a bellwether case, agreeing with defendant Sanofi-Aventis US LLC that the plaintiff filed her claim beyond Mississippi’s statute of limitations.

  • January 25, 2021

    Trump Pardons Ex-Drug Exec Harkonen For 2009 Wire Fraud Conviction

    WASHINGTON, D.C. — Outgoing President Donald Trump on Jan. 19 pardoned former InterMune Inc. CEO W. Scott Harkonen, M.D., for his 2009 wire fraud conviction for misrepresenting clinical study results purporting to show that drug Actimmune was effective in treating idiopathic pulmonary fibrosis (IPF).

  • January 22, 2021

    Insys Founder Kapoor To Pay Up To $5M To Settle New Jersey Lawsuit

    NEW BRUNSWICK, N.J. — The founder of opioids maker Insys Therapeutics Inc. on Jan. 21 signed a consent judgment in New Jersey state court agreeing to pay up to $5 million to resolve a consumer fraud and false claims civil lawsuit brought by the state attorney general for allegedly paying bribes for doctors to prescribe the fentanyl-based pain drug Subsys.

  • January 22, 2021

    ‘Biotech Expert’ Arrested For Peddling Misbranded COVID-19 Vaccine

    SEATTLE — The U.S. Attorney’s Office for the Western District of Washington on Jan. 21 announced that it arrested Johnny T. Stine, 55, of Redmond, Wash., on a federal misdemeanor charge of introducing misbranded drugs into interstate commerce for claiming to have a COVID-19 vaccine available to paying customers.

  • January 21, 2021

    Health Care Company Pays $7.75M To Resolve DEA Drug Diversion Probe

    Health care company McLaren Health Care Corp. will pay $7.75 million to resolve a federal investigation that two of its former retail pharmacies violated the Controlled Substances Act by failing to properly account for Schedule II drugs, according to Jan. 19 announcements by two U.S. attorneys and McLaren.

  • January 19, 2021

    Mass Tort Cases For Drugs, Medical Devices

    New developments in the following mass tort drug and device cases are marked in boldface type.

  • January 19, 2021

    United States Opposes Motion By Theranos Founder To Exclude ‘Anecdotal’ Lab Tests

    SAN JOSE, Calif. — The United States on Jan. 11 opposed a motion by former Theranos Inc. founder Elizabeth Holmes to exclude “anecdotal test results” from her upcoming criminal fraud trial, telling a California court that the company gave the government a password-blocked copy of its test database then dismantled the server on which the data was stored.

Can't find the article you're looking for? Click here to search the Mealey's Drugs & Devices archive.